- Home
- YHGJ vs MBRX Comparison
YHGJ vs MBRX Comparison
Compare YHGJ & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YHGJ
- MBRX
- Stock Information
- Founded
- YHGJ 1975
- MBRX 2015
- Country
- YHGJ United States
- MBRX United States
- Employees
- YHGJ N/A
- MBRX N/A
- Industry
- YHGJ Specialty Chemicals
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- YHGJ Industrials
- MBRX Health Care
- Exchange
- YHGJ Nasdaq
- MBRX Nasdaq
- Market Cap
- YHGJ 17.1M
- MBRX 17.1M
- IPO Year
- YHGJ 1997
- MBRX 2016
- Fundamental
- Price
- YHGJ $0.54
- MBRX $0.41
- Analyst Decision
- YHGJ
- MBRX Strong Buy
- Analyst Count
- YHGJ 0
- MBRX 4
- Target Price
- YHGJ N/A
- MBRX $5.00
- AVG Volume (30 Days)
- YHGJ 191.1K
- MBRX 4.9M
- Earning Date
- YHGJ 11-07-2025
- MBRX 11-07-2025
- Dividend Yield
- YHGJ N/A
- MBRX N/A
- EPS Growth
- YHGJ N/A
- MBRX N/A
- EPS
- YHGJ N/A
- MBRX N/A
- Revenue
- YHGJ $18,964,000.00
- MBRX N/A
- Revenue This Year
- YHGJ N/A
- MBRX N/A
- Revenue Next Year
- YHGJ N/A
- MBRX N/A
- P/E Ratio
- YHGJ N/A
- MBRX N/A
- Revenue Growth
- YHGJ 5.70
- MBRX N/A
- 52 Week Low
- YHGJ $0.43
- MBRX $0.25
- 52 Week High
- YHGJ $1.27
- MBRX $3.65
- Technical
- Relative Strength Index (RSI)
- YHGJ 39.28
- MBRX 42.31
- Support Level
- YHGJ $0.56
- MBRX $0.36
- Resistance Level
- YHGJ $0.68
- MBRX $0.42
- Average True Range (ATR)
- YHGJ 0.06
- MBRX 0.03
- MACD
- YHGJ 0.00
- MBRX 0.01
- Stochastic Oscillator
- YHGJ 10.00
- MBRX 85.53
About YHGJ Yunhong Green CTI Ltd.
Yunhong Green CTI Ltd manufactures and marketers of foil balloons and produces laminated and printed films for commercial uses. The company also distributes balloon-inspired and other gift items, and continues development of compostable material solutions, and markets its products throughout the United States and in several other countries.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.